Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
A phase 3 trial of Tebentafusp, Pembrolizumab in melanoma, run by Immunocore Ltd, now recruiting.
Overview
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) is a phase 3 interventional study registered as NCT05549297 by Immunocore Ltd, with 540 participants planned, started 2022-12-19 and due to reach its primary completion in 2028-03. Interventions recorded: Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice. Conditions listed: Advanced Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSafety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Shares Immunocore, Tebentafusp, Pembrolizumab.
- TrialIMCgp100-202
Shares Immunocore, Tebentafusp, Melanoma.
- TrialPRISM-MEL-301
Shares Immunocore, Melanoma.
- TreatmentBrenetafusp
Shares Immunocore, Tebentafusp, Melanoma.
- PersonPaul Nathan
Shares Tebentafusp, Melanoma.
- IdeaTCR therapeutics for non-HLA-A*02 patients
Shares Tebentafusp, Melanoma.
- IdeaAntibodies that see mutant KRAS and p53 fragments displayed on the cell surface
Shares Immunocore, Tebentafusp.
- PersonRichard D. Carvajal
Shares Tebentafusp, Melanoma.